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corresponding vehicle resulted in statistically significant im-
proved wound healing with an earlier onset of healing in 
particular. Based on these results obtained using an abrasive 
wound model, it can be concluded that the addition of tyro-
thricin 0.1% to the gel vehicle did not interfere with the im-
proved wound healing seen with the vehicle alone. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 There is a high incidence of small, superficial, acute 
wounds which are mainly caused by minor cuts, minor 
burn injuries (superficial, second degree) or accidental 
abrasive trauma during sport participation or other daily 
activities. Dirt or bacteria may have been incorporated 
into the fresh wounds. These wounds involve the epider-
mis and sometimes the superficial portion of the dermis. 
They are erythematous and mildly painful  [1] . People gen-
erally treat such minor everyday wounds themselves, usu-
ally with dressings or wound gels and ointments with or 
without antibacterial ingredients which do not interfere 
with healing and ideally result in enhanced wound heal-
ing irrespective of microbial colonization. Topical agents 
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 Abstract 
 Background: Topical preparations are a common treatment 
for superficial acute wounds, which at the least do not inter-
fere with healing and ideally result in enhanced wound heal-
ing irrespective of microbial colonization.  Objective: To ex-
amine the effects of a topical antimicrobial gel and its vehicle 
on the wound healing of standardized, superficial abrasions. 
 Methods: Thirty-three healthy volunteers were enrolled in
a double-blinded, randomized, intraindividual comparison 
study. Three standardized, superficial abrasions were in-
duced on their forearms. A tyrothricin 0.1% gel (Tyrosur  gel; 
Engelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, 
Germany) and its vehicle were randomly applied to two of 
the test areas, and one lesion remained untreated.  Results: 
A significant improvement of wound healing was seen with 
both tyrothricin 0.1% gel and its corresponding vehicle in the 
clinical assessment. The mean area under the curve (AUC) of 
wound healing scores was the same for both preparations 
and the mean reepithelization scores were comparable at all 
test points over the entire 12 days. A lower mean AUC repre-
senting less reepithelization was found for the untreated 
test fields.  Conclusion: The use of tyrothricin 0.1% gel and its 
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and a dressing that is minimally restrictive may be of ad-
vantage especially in wounds that are located over joints 
due to the limitation of movement and contracture of the 
skin  [2] . In general, products that promote a moist wound 
environment produce better results in wound healing 
than those that promote a dry environment  [3–12] . More-
over, with any open wound skin infection an increased 
risk of systemic infection accompanies prolonged healing. 
Infected wounds might also scar more severely. Therefore, 
the treatment with topical agents in burn and wound care 
should also take into consideration the risk of additional 
skin infection  [2] . Common bacterial pathogens relevant 
for skin infections include Gram-positive bacteria (e.g. 
 Streptococcus pyogenes, Staphylococcus aureus ) and Gram-
negative bacteria (e.g. Pseudomonas aeruginosa )  [13] , 
while  Candida is a common source of – rarer – fungal in-
fections  [14] . Correspondingly, a large variety of topical 
antimicrobial agents such as bacitracin, polymyxin B sul-
fate, neomycin, povidone-iodine, silver sulfadiazine, 
gentamycin, nystatin and others are used in wound care 
 [2] . Tyrothricin, an antimicrobial peptide (AMP), was 
identified and found its way into clinical application de-
cades before its mode of action was uncovered  [15] . AMPs 
are small, cationic, amphiphilic peptides with broad-
spectrum microbicidal activity against both bacteria and 
fungi  [16] . Furthermore, AMPs might help to overcome 
the growing problems of antibiotic resistance in the treat-
ment of infectious skin diseases due to their special mode 
of action against microorganisms, namely, directly target-
ing and destroying their membranes  [17–19] . Tyrothricin 
is a polypeptide antibiotic produced by  Bacillus brevis  [20] 
consisting of the two cyclic decapeptides gramicidin S and 
tyrocidine A  [21] . Both peptides have broad bactericidal 
activity against Gram-positive bacteria; tyrothricin has 
been shown not to pose a risk with respect to acquired re-
sistance of originally susceptible Gram-positive bacteria 
and yeasts, not even in the case of  S. aureus , both with 
MSSA and MRSA strains [Korting et al., unpubl. data]. In 
a pilot study, a tyrothricin-containing wound gel (Tyro-
sur  gel; Engelhard Arzneimittel GmbH & Co. KG, Nie-
derdorfelden, Germany) showed an improvement in the 
healing of noninfected wounds indicated by a higher lev-
el of reepithelization compared to the untreated test field 
[bioskin GmbH, unpubl. data]. The wound gel, its vehicle 
and a positive control (an ointment containing dexpan-
thenol) were applied once daily over a 12-day treatment 
period under semiocclusive conditions. The data support-
ed the decision to perform the present confirmatory study 
with the aim of proving significantly better wound heal-
ing efficacy compared to untreated wounds. Since the 
broad antimicrobial effect of tyrothricin has been estab-
lished for years and for feasibility/ethical reasons, only the 
possible direct wound healing effect beyond antimicro-
bial activity was investigated here using a recently pub-
lished wound model based on noninfected wound lesions 
only  [22] . It was important to establish that tyrothricin 
would have no hindering effects on improved wound 
healing observed when using the vehicle alone. 
 Methods 
 Volunteers 
 The study was performed at bioskin GmbH, Hamburg, Ger-
many, from September 23 to October 8, 2010. The selection of 
subjects was in accordance with the requirements of the German 
drug law as well as the recommendations of the currently valid 
revision of the Helsinki Declaration and the ICH-GCP guide-
lines. The study documents were approved by the ethics commit-
tee of the Hamburg Medical Council. The study was registered at 
the competent authorities. Written informed consent was ob-
tained from 33 male or female volunteers, aged 18 years or older 
with healthy skin in the test area before the start of the study. The 
33 volunteers were randomized (20 women and 13 men, mean age 
42.6 years, range 23–58 years). The following were the main exclu-
sion criteria: relevant dermatological diseases such as psoriasis or 
lichen ruber planus; suntan, hyperpigmentation or tattoos in the 
test fields; dark-skinned persons; diabetes; history of wound-
healing complications, or keloid and hypertrophic scarring; any 
clinically significant illness 4 weeks before and during the trial; 
known allergic reactions to components of the investigational 
products, and treatment with systemic or locally acting medica-
tions (e.g. antihistamines or glucocorticosteroids) within 2 weeks 
before the first treatment. The use of topical products other than 
the investigational products in the test fields was prohibited dur-
ing the clinical trial. Bathing, sauna and sunbathing were not al-
lowed. The adhesive bandages used for semiocclusion were not to 
be soaked through since the wound healing of the test fields might 
have been influenced. For the same reason exercise causing exces-
sive sweating had to be avoided.
 Test Design  [22] 
 After enrollment 3 small superficial, abrasive wounds (10 mm 
in diameter) were induced, 2 on the right forearm and 1 on the left 
forearm of each volunteer. Treatment with tyrothricin 0.1% gel 
(Tyrosur gel; Engelhard Arzneimittel) and its vehicle (excipients: 
cetylpyridinium chloride, purified water, propylene glycol, etha-
nol 96%, carbomer, Trometamol) was performed topically under 
semiocclusive conditions. Approximately 100   l of the formula-
tions were applied with a gloved finger to the respective test fields 
on the volar forearm once daily over a 12-day study period (11 
treatments, days 1–11). One test field remained untreated and 
served as control. All 3 wounds were covered with semiocclusive 
patches (Hansaplast Soft Med, hypoallergic without antiseptic sil-
ver). Wound healing was clinically assessed in all 3 test fields on 
days 2, 5, 8 and 12. Adverse events were recorded on each day over 
the entire study period.
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 Induction of Superficial Wounds 
 Before wounding, the forearms were disinfected with an anti-
septic solution (Softasept  N; Braun, Melsungen, Germany). Two 
disinfected templates (robust plastic sheets) were applied to the 
skin. One template contained two holes (right forearm) and the 
other one hole (left forearm) with a diameter of 10 mm. The dis-
tance between the two holes on the right forearm was at least 1.5 
cm. Epidermal abrasive wounds were induced under visual con-
trol by the same trained study nurse who repeatedly scrubbed the 
skin with a sterile surgical hand brush using moderate pressure 
until the first signs of uniform glistening and punctual bleeding 
were observed. At this point, the scrubbing was stopped to ensure 
that the lesion was superficial with only partial erosion of the pap-
illary dermis. This procedure caused only minor pain, thus no 
local anesthetic was necessary  [22] .
 Clinical Assessment of Wound Healing 
 After the removal of the patches and product residues the clin-
ical assessment was performed by a trained investigator, based on 
the level of reepithelization represented by the following score 
 [22] :  0 = 0% healing, 1 = 1–25% reepithelization, 2 = 26–50% reep-
ithelization, 3 = 51–75% reepithelization, 4 =  1 75% but not com-
plete reepithelization and 5 = 100% complete healing.
 Statistics 
 Wound healing scores and their area under the time curve 
(AUC) were summarized. The AUC was calculated using the lin-
ear trapezoidal rule and the data assessed on days 5, 8 and 12. The 
hypotheses on the differences in AUCs of the wound healing 
scores between 0.1% tyrothricin gel and untreated as well as be-
tween the vehicle and untreated were tested by the exact Wilcox-
on signed-rank test at level   = 0.025. For evaluation of the safety 
extent of exposure to the investigational products, adverse events 
and vital signs were analyzed.
 Results 
 The data from all 33 subjects were valid for the safety 
and intent-to-treat analyses while data from 32 volun-
teers were valid for the per protocol analysis. One subject 
was excluded from the per protocol analysis due to the 
use of a prohibited concomitant medication. Since the re-
sults of the intent-to-treat analysis were similar to those 
of the per protocol analysis only the results of the intent-
to-treat are presented. Mean absolute clinical assessment 
scores are presented in  figure 1 . The tyrothricin 0.1% gel 
and the corresponding vehicle showed a comparable 
course of mean scores in the clinical assessment of reepi-
thelization of superficial wounds at all test points (day 5: 
0.9 and 0.8, respectively; day 8: 2.7 each; day 12: 4.4 and 
4.5, respectively). The median reepithelization scores for 
days 5, 8 and 12 were 1.0, 3.0 and 5.0, respectively, for both 
investigational products. A comparable mean reepitheli-
zation score was noted for the untreated test field com-
pared to both treated test fields on day 5 (0.8) and lower 
reepithelization scores were noted on days 8 and 12 (2.2 
and 3.6, respectively). For the untreated field the median 
reepithelization scores for days 5, 8 and 12 were 1.0, 2.0 
and 4.0, respectively. At the end of the 12-day treatment 
period complete healing was noted in more than half of 
the subjects in the test fields treated with tyrothricin
0.1 % gel (51.5%) and the vehicle (63.6%). In these test 
fields reepithelization was  1 75% in 39.4% (tyrothricin 
0.1% gel) and 27.3% (vehicle) of the subjects and reepithe-
lization of 51–75% was noted in 9.1% of the subjects for 
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 Fig. 1. Course of mean scores (absolute val-
ues) in the clinical assessment of reepithe-
lization of superficial wounds following 
treatment with Tyrosur gel and corre-
sponding vehicle and untreated test field. 
Clinical assessment was performed using 
a 6-point scale (0 = 0% healing, 1 = 1–25% 
reepithelization, 2 = 26–50% reepitheliza-
tion, 3 = 51–75% reepithelization, 4 =  1 75% 
but not complete reepithelization and 5 = 
100% complete healing). Values are pre-
sented as means  8 SD. 
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each treatment. For the untreated test field complete 
healing was noted in fewer subjects (30.3%). Reepitheliza-
tion of  1 50% was noted in 42.5% of the subjects ( 1 75%: 
36.4%; 51–75%: 6.1%) and reepithelization  ! 50% in ap-
proximately 25% of the subjects. In 1 subject no healing 
in the untreated field was seen at the end of the trial. 
Mean AUCs of wound healing scores are presented in  fig-
ure 2 . The mean AUC of wound healing scores was the 
same for tyrothricin 0.1% gel and the vehicle (19.7 arbi-
trary units each). A lower mean AUC was calculated for 
the untreated test fields (15.9 arbitrary units). The treat-
ment comparisons showed greater mean AUCs for tyro-
thricin 0.1% gel and the vehicle (p = 0.0001 and 0.0008, 
respectively) compared to the untreated test fields. Fur-
thermore, the noninferiority of tyrothricin 0.1% gel to the 
vehicle could be demonstrated. Altogether five nonseri-
ous adverse events were reported in 3 subjects. None of 
these were located in the test fields and none were consid-
ered to be related to the study medication.
 Discussion 
 The focus of this investigation was to assess the effect 
of tyrothricin on noninfected wounds with respect to in-
terference and influence on wound healing irrespective 
of microbial colonization. The topical use of tyrothricin 
in wound healing has been established over decades. It 
has been shown to be effective in skin infection both in 
vitro and in vivo  [23] . In a prospective, randomized mul-
ticenter trial of 131 patients with posttraumatic and
surgical cutaneous lesions a tyrothricin-containing pow-
der demonstrated superior efficacy compared to placebo 
powder with respect to the radius of lesions as well as to 
a wound index  [23] . There is an increasing interest in 
AMPs such as tyrothricin because these ‘nature’s antibi-
otics’ are promising agents for virtually new therapeutic 
approaches in infectious diseases, especially of the skin 
and for wound healing  [24] . The well-known antimicro-
bial properties of tyrothricin also apply to the tyrothricin 
0.1% gel tested in this study. Therefore, the focus of the 
present study was to assess the improvement of wound 
healing in superficial noninfected wounds by tyrothricin 
0.1% gel and its vehicle in comparison to an untreated test 
field, independent of the antimicrobial properties. It was 
necessary to confirm that the composition of the vehicle 
contributes to improved wound healing and that the ac-
tive antimicrobial ingredient tyrothricin does not inter-
fere with this improved wound healing in noninfected 
superficial wounds. A recently published wound model 
inducing multiple uniform abrasions presents a new way 
to evaluate intraindividually the healing properties of 
commonly applied products in superficial wounds as-
sessed by a clinical reepithelization score  [22] . So far, only 
limited data are available on the examination of acute 
wounds and dressing techniques to guide clinical deci-
sions  [25, 26] and only few standardized protocols in the 
literature describe specific methods to examine acute 
wound healing  [27, 28] . In another published abrasion 
model to examine the effects of occlusive dressings, 
wound healing was measured by change in wound con-
traction (cm 2 ) and change in wound color (skin color 
measurements of redness by chromametry), and it was 
demonstrated that occlusive dressings providing a moist 
wound environment are more effective than dry wound 
healing  [10] . In this model, partial-thickness wounds 
were induced on the lower part of the leg using weighted 
sandpaper after the skin had been pretreated with an an-
esthetic ointment. Wound models remain the most effec-
tive way of objectively measuring the effects of treatment 
for acute superficial wounds in a clinical setting. The 
model used here has been published in the context of a 
pilot study with 10 volunteers treated with different plas-
ters, demonstrating the benefit of moist wound healing 
 [22] . This is the first time the model has been used in a 
confirmatory study with a larger number of volunteers
(n = 33) treated with a topical wound gel. The wounds 
reflect the main aspects of the clinical situation of super-
0
4
8
12
16
20
24
28
32
36
A
U
C
 o
f w
ou
n
d
 h
ea
lin
g
 s
co
re
s
(a
rb
it
ra
ry
 u
n
it
s)
p = 0.0001
p = 0.0008
Tyrothricin 0.1% Vehicle Untreated test field
 Fig. 2. AUC of wound healing scores and comparisons versus un-
treated test field using paired t test. Statistically significant great-
er mean AUCs were found for Tyrosur gel and the vehicle (p = 
0.0001 and 0.0008, respectively) compared to the untreated test 
field. Values are presented as means  8 SD. 
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ficial wounds such as partial abrasion of the epidermis, 
punctual bleeding and glistening. A key advantage com-
pared to other models is that no local anesthetic is re-
quired and, therefore, subjective tolerability of products 
can be assessed from the first application onwards. In the 
present study with once daily, semiocclusive application 
over a 12-day treatment period, tyrothricin 0.1% gel and 
the corresponding vehicle both showed a significant pos-
itive effect on wound healing as reflected by the same 
mean AUCs of wound healing scores.
 A limitation of this paper is the lack of a comparison 
between the tyrothricin gel 0.1% and its vehicle and a ref-
erence hydroactive colloid gel.
 Overall, the results showed that the totality of ingredi-
ents of the vehicle and correspondingly of the tyrothricin 
0.1% gel had a positive effect on wound healing compared 
to untreated test fields even under semiocclusive condi-
tions. The addition of tyrothricin to the vehicle did not 
interfere with the positive effects noted for the vehicle 
alone. Taken together with the proven antimicrobial ef-
fect of tyrothricin, tyrothricin 1% gel can be recommend-
ed for the treatment of superficial acute wounds to pro-
mote wound healing.
 Disclosure Statement 
 The preparation of this manuscript was supported by a grant 
from Engelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, 
Germany. Dr. Wigger-Alberti, R. Williams and K. Grigo per-
formed and analyzed the trial on a contract research basis. Prof. 
Korting collaborated with Engelhard Arzneimittel GmbH in the 
development of topical drugs for skin diseases. Dr. Stauss-Grabo 
and S. Atiye are employed by the company that supported this 
investigation but do not have any personal financial interest in the 
investigation described in the manuscript. Data analysis and in-
terpretation were not influenced by the company.
 
 References 
 1 Solem L: Classification; in Fischer SV, Helm 
PA (eds): Comprehensive Rehabilitation of 
Burns. Baltimore, Williams & Wilkins, 
1984, pp 9–15. 
 2 Ward RS, Saffle JR: Topical agents in burn 
and wound care. Phys Ther 1995; 75: 526–538. 
 3 Kannon GA, Garret AB: Moist wound heal-
ing with occlusive dressings. Dermatol Surg 
1995; 21: 583–590. 
 4 Winter G: Formation of the scab and the rate 
of epithelialisation of superficial wounds in 
the skin of the young domestic pig. Nature 
1962; 193: 293–295. 
 5 Cho CY, Lo JS: Dressing the part. Dermatol 
Clin 1998; 16: 25–47. 
 6 Eaglestein WH: Occlusive dressings. J Der-
matol Surg Oncol 1993; 19: 716–720. 
 7 Ågren MS, Karlsmark T, Hansen JB, Rygaard 
J: Occlusion versus air exposure on full-
thickness biopsy wounds. J Wound Care 
2001; 10: 301–304. 
 8 Silverman RA, Lender J, Elmets CA: Effects 
of occlusive and semiocclusive dressings on 
the return of barrier function to transepider-
mal water loss in standardized human 
wounds. J Am Acad Dermatol 1989; 20: 755–
760. 
 9 Beam JW: Management of superficial to par-
tial-thickness wounds. J Athl Train 2007; 42: 
 422–424. 
 10 Beam JW: Occlusive dressings and the heal-
ing of standardized abrasions. J Athl Train 
2008; 43: 600–607. 
 11 Thomas S: Hydrocolloid dressings in the 
management of acute wounds: a review of the 
literature. Int Wound J 2008; 5: 602–613. 
 12 Korting HC, Schöllmann C, White R: Man-
agement of minor acute cutaneous wounds: 
importance of wound healing in a moist en-
vironment. J Eur Acad Dermatol Venereol 
2011; 25: 130–137. 
 13 Harkess N: Bacteriology; in Kloth LC, Mc-
Culloch JM, Feedar JA (eds): Wound Heal-
ing: Alternatives in Management. Philadel-
phia, Davis, 1990, pp 60–61. 
 14 Hill MJ: Infections; in Hill MJ (ed): Skin Dis-
orders. St Louis, Mosby Year Book, 1994, pp 
89–93. 
 15 Korting HC, Schöllmann C, Stauss-Grabo 
M, Schäfer-Korting M: Antimicrobial pep-
tides and skin: a paradigm of translational 
medicine. Skin Pharmacol Physiol 2012; 25: 
 323–324. 
 16 Schneider JJ, Unholzer A, Schaller M, 
Schäfer-Korting M, Korting HC: Human de-
fensins. J Mol Med 2005; 83: 587–595. 
 17 Wang Z, Wang G: APD: the antimicrobial 
peptide database. Nucleic Acids Res 2004; 32: 
 590–592. 
 18 Khandelia H, Ipsen JH, Mouritsen OG: The 
impact of peptides on lipid membranes. Bio-
chem Biophys Acta 2008; 1778: 1528–1536. 
 19 Bradshaw J: Cationic antimicrobial peptides: 
issues for potential clinical use. BioDrugs 
2003; 17: 233–240. 
 20 Dubos RJ: Studies on a bactericidal agent ex-
tracted from a soil bacillus. J Exp Med 1939; 
 70: 249–256, in Tang XU, Thibault, Boyd RK: 
Characterisation of the tyrothricin and gram-
icidin fractions of the tyrothricin complex 
from  Bacillus brevis using liquid chromatog-
raphy and mass spectrometry. Int J Mass 
Spectroscop Ion Proc 1992; 122: 153–179. 
 21 Franklin TJ, Snow GA: Biochemistry of An-
timicrobial Action. New York, Chapman & 
Hall, 1988, pp 61–64. 
 22 Wigger-Alberti W, Kuhlmann M, Ekanay-
ake S, Wilhelm D, Buettner H, Callaghan T, 
Wilhelm KP: Using a novel wound model to 
investigate the healing properties of prod-
ucts for superficial wounds. J Wound Care 
2009; 18: 123–131. 
 23 Bayerl C, Völp A: Tyrothricin powder in the 
treatment of cutaneous lesions (in German). 
Die Pharmazie 2004; 59: 864–868. 
 24 Steinstraesser L, Koehler T, Jacobsen F, 
Daigeler A, Goertz O, Langer S, Kesting M, 
Steinau H, Eriksson E, Hirsch T: Host de-
fense peptides in wound healing. Mol Med 
2008; 14: 528–537. 
 25 Claus EE, Fusco CF, Ingram T, Ingersoll CD, 
Edwards JE, Melham TJ: Comparison of the 
effects of selected dressings on the healing of 
standardized abrasions. J Athl Train 1998; 
 33: 145–149. 
 26 Wiechula R: The use of moist wound-healing 
dressings in the management of split-thick-
ness skin graft donor sites: a systematic re-
view. Int J Nurs Pract 2003; 9: 9–17. 
 27 Schultz G, Mozingo D, Romanelli M, Clax-
ton K: Wound healing and TIME: new con-
cepts and scientific applications. Wound Re-
pair Regen 2005; 13: 1–11. 
 28 Keast DH, Bowering K, Evans AW, MacKean 
GL, Burrows C, D’Souza L: MEASURE: a 
proposed assessment framework for devel-
oping best practice recommendations for 
wound assessment. Wound Repair Regen 
2004; 12: 1–17. 
 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 2
:3
3:
39
 P
M
